Table 1 Antimicrobial susceptibility of Gram-negative bacteria isolated from patients with healthcare-associated meningitis from 2004 to 2019 (n = 383)
| Â | Klebsiella spp.a | Other Enterobacteralesb | Acinetobacter spp.c | Pseudomonas aeruginosa | Stenotrophomonas maltophilia | Othersd | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antimicrobials | (n = 106) | (n = 39) | (n = 170) | (n = 37) | (n = 19) | (n = 12) | ||||||
S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | |
Piperacillin | 7.5 | 90.6 | 23.1 | 76.9 | 11.2 | 75.9 | 54.1 | 13.5 | NA | NA | 58.3 | 33.3 |
Piperacillin-tazobactam | 40.6 | 58.5 | 84.6 | 15.4 | 22.4 | 65.9 | 62.2 | 8.1 | NA | NA | 58.3 | 41.7 |
Cefotaxime | 13.2 | 86.8 | 25.6 | 74.4 | 10.6 | 77.6 | NA | NA | NA | NA | 8.3 | 50.0 |
Ceftazidime | 20.8 | 73.6 | 51.3 | 48.7 | 21.2 | 78.2 | 62.2 | 37.8 | 31.6 | 52.6 | 16.7 | 75.0 |
Cefepime | 35.8 | 55.7 | 46.2 | 35.9 | 24.1 | 57.1 | 73.0 | 13.5 | NA | NA | 8.3 | 83.3 |
Cefoperazone-sulbactam | 28.3 | 55.7 | 64.1 | 23.1 | 35.3 | 22.9 | 62.2 | 16.2 | 73.7 | 21.1 | 58.3 | 33.3 |
Imipenem | 50.9 | 43.4 | 94.9 | 5.1 | 40.6 | 50.0 | 48.6 | 24.3 | NA | NA | 33.3 | 66.7 |
Meropenem | 51.9 | 42.5 | 97.4 | 2.6 | 42.9 | 50.6 | 37.8 | 27.0 | NA | NA | 16.7 | 66.7 |
Amikacin | 49.1 | 50.9 | 76.9 | 23.1 | 26.5 | 72.9 | 78.4 | 21.6 | NA | NA | 16.7 | 66.7 |
Minocycline | 59.4 | 24.5 | 48.7 | 33.3 | 48.8 | 25.3 | NA | NA | 84.2 | 5.3 | 100.0 | 0.0 |
Ciprofloxacin | 28.3 | 67.0 | 43.6 | 56.4 | 15.9 | 81.8 | 62.2 | 37.8 | NA | NA | 8.3 | 75.0 |
SXT | 56.6 | 43.4 | 46.2 | 53.8 | 37.1 | 62.9 | NA | NA | 73.7 | 26.3 | 75.0 | 25.0 |
Fosfomycin | 67.0 | 31.1 | 76.9 | 23.1 | NA | NA | NA | NA | NA | NA | NA | NA |
Tigecycline | 95.3 | 2.8 | 84.6 | 15.4 | 52.4 | 22.4 | NA | NA | 68.4 | 21.1 | 41.7 | 41.7 |